stockrowViatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) Operating cash flow
Viatris Inc.'s operating cash flow for fiscal 2025 was $2.3B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $2.5B. Over the past ten years it has ranged from $1.2B (fiscal 2020) to $3.0B (fiscal 2021); the current reading is higher than 64% of that period. Viatris Inc. ranks 4th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $2.3B | 0.56% |
| FY2024 | $2.3B | (20.59%) |
| FY2023 | $2.9B | (3.30%) |
| FY2022 | $3.0B | (0.59%) |
| FY2021 | $3.0B | 144.92% |
| FY2020 | $1.2B | (31.71%) |
| FY2019 | $1.8B | (22.97%) |
| FY2018 | $2.3B | 13.41% |
| FY2017 | $2.1B | 0.86% |
| FY2016 | $2.0B | 1.93% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $899.4M | 135.57% |
| Jun 2026 | $381.8M | (1.67%) |
| Mar 2026 | $388.3M | (52.40%) |
| Dec 2025 | $815.8M | 9.52% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.8B |
| ZTS Zoetis Inc. compare | $2.8B |
| VTRS Viatris Inc. | $2.5B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.8B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| ALKS Alkermes plc compare | $243.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement